ccr 5

CCR5 antagonist 1, derived from WO 2004054974 A2, is a CCR5 antagonist that inhibits HIV replication.

CCR5-IN-1 (compound 3ad) is an allosteric, selective inhibitor of CCR5 with an IC50 of 1.09 μM. It is applicable in research related to cardiovascular, central nervous system, immune system, and infectious diseases.

CCR5modulator-1 (Compound 26) acts as a modulator of CCR5 and is useful for studies related to inflammation.

Anti-CCR5 Antibody (HEK/1/85a/7a) is an antibody targeting CCR5 and can be used for immunology research.

Anti-Mouse CCR5 Antibody (C5Mab-2) is an antibody targeting CCR5 and can be used for immunology research.

Aplaviroc (AK 602), an SDP derivative, is a CCR5 antagonist with IC50 values of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL, and HIV-1MOKW.

INCB-9471 is a CCR5 antagonist with anti-HIV activity and inhibits the interaction between HIV-1 gp120.

Vicriviroc maleate (SCH-417690 (maleate))(Sch-417690) is a piperazine-based CCR5 receptor antagonist with activity against human immunodeficiency virus. The IC50 value is 0.91 nM in clinical development for the treatment of HIV-1.

Cenicriviroc Mesylate is a dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2 with anti-inflammatory and antiinfective activity.

PF-0463481 is safe and well-tolerated and has the potential for the study of diabetic nephropathy. PF-0463481 is an effective and orally active dual CCR2/CCR5 antagonist. It also has comparable human and rodent CCR2 potency (rat IC50=20.8 nM). PF-0463481

CCX140 (CCX140-B) (CCX140-B) is an antagonist of CCR2.

AZD-5672 is an antagonist of CCR5 with an IC50 of 0.32 nM. AZD-5672 inhibits hERG cardiac ion channel binding and P-gp-mediated digoxin transport with IC50s of 7.3 μM and 32 μM. AZD-5672 can be used in studies about rheumatoid arthritis.

BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.

DAPTA (Adaptavir) is an inhibitor of CCR5, shows potent anti-HIV activities.

Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody with both anti-HIV and anti-tumor activity, inhibiting CCR-mediated HIV-1 virus and cancer cell metastasis in mouse tumor models. Leronlimab can be used to study HIV, non-alcoholic steatohepatitis (NASH), and breast cancer.

WAY-639418 has potential anti-inflammatory and anti-HIV activity and can be used to study CCR5-mediated inflammatory and immunomodulatory diseases.

Cenicriviroc (TAK-652) is an orally active, dual CCR2/CCR5 antagonist that inhibits both HIV-1 and HIV-2, exhibiting potent anti-infective and anti-inflammatory activity.

TAK-220 is a selective and orally bioavailable CCR5 antagonist with IC50 values of 3.5 nM for RANTES binding inhibition and 1.4 nM for MIP-1α binding inhibition to CCR5.

HIV-1 inhibitor-6 (3-Pyridinecarboxamide, 1,4-dihydro-1-methyl-N-(5-nitro-1,2-benzisothiazol-3-yl)-4-oxo-) is a potent HIV-1 pre-mRNA selective splicing inhibitor that blocks HIV replication.

CCR2 antagonist 5 (JNJ-41443532) is a selective and orally active hCCR2 inhibitor with good binding affinity (IC50=37 nM) and potent functional antagonism (chemotaxis IC50=30 nM).JNJ-41443532 binds mCCR2 with a Ki of 9.6 µM, which can be used to study inflammatory diseases and diabetes. diseases and diabetes.

CCR1/5/8 activator 1 is a cytoplasmic phospholipase A inhibitor with antifungal activity.

AF-399/42018025 is a small-molecule antagonist of CC chemokine receptor 4 (CCR4) utilized as a research tool to investigate CCR4-mediated immune cell trafficking, inflammatory signaling, and chemokine-driven disease mechanisms, supporting studies in immunology, oncology, and inflammatory disorder models.

INCB10820 is an efficient and specific dual antagonist of CCR2 and CCR5, with oral bioavailability.

CB-0821 is a high-affinity CCR5 inhibitor with a Ki of 0.04 nM. It effectively binds to the hydrophobic pocket of the CCR5 protein, hindering the interaction between viral proteins and CCR5, thereby blocking virus entry. CB-0821 holds potential for anti-HIV research.